<DOC>
	<DOCNO>NCT01303640</DOCNO>
	<brief_summary>The purpose study evaluate whether newly-approved biolimus-eluting stent inferior everolimus-eluting stent term rate target-lesion revascularization 1-year death myocardial infarction 3-year stent implantation real world clinical practice .</brief_summary>
	<brief_title>NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial</brief_title>
	<detailed_description>Everolimus-eluting stent widely use coronary drug-eluting stent Japan . Biolimus-eluting stent new coronary drug-eluting stent , go approved 2011 Japanese Ministry Health , Labor Welfare . It report biolimus-eluting stent low rate target-lesion revascularization stent thrombosis 9 month compare paclitaxel-eluting stent . However , trial result compare biolimus-eluting stent everolimus-eluting stent largely unknown . The purpose study evaluate whether newly-approved biolimus-eluting stent inferior everolimus-eluting stent term rate target-lesion revascularization 1-year death myocardial infarction 3-year stent implantation real world clinical practice . The design study all-comer design enrol patient schedule percutaneous coronary intervention use drug-eluting stent without exclusion criterion .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients schedule percutaneous coronary intervention use drugeluting stent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Coronary stent</keyword>
</DOC>